source
- Lilly presents safety data on obesity drug retatrutide, noting rare cardiac eventsEli Lilly reported new safety and tolerability findings for its next-generation obesity therapy retatrutide at the American Diabetes Association annual meeting. In the study, 7 of the 403 particip…
- Pfizer’s monthly obesity drug berobenatide shows up to 12% weight loss in mid-stage VESPER-3 studyDetailed data from Pfizer's mid‑stage VESPER-3 trial indicate that the company’s monthly‑dosed obesity candidate, berobenatide, continues to demonstrate weight‑loss potential. The drug, originally…